Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 28, 2013; 19(24): 3872-3882
Published online Jun 28, 2013. doi: 10.3748/wjg.v19.i24.3872
Published online Jun 28, 2013. doi: 10.3748/wjg.v19.i24.3872
Table 2 Prognosis of patients reported in the trials included in the meta-analysis
| Ref. | Treatment | No. of patients | Recurrence- free survival rate | Overall survival rate | |||||
| 1 yr | 3 yr | 5 yr | 1 yr | 2 yr | 3 yr | 5 yr | |||
| Peng et al[14] | TACE+RFA | 69 | 80.00% | 45.00% | 40.00% | 94.00% | NA | 69.00% | 46.00% |
| RFA | 70 | 64.00% | 18.00% | 18.00% | 82.00% | 47.00% | 36.00% | ||
| Cheng et al[15] | TACE+RFA | 96 | NA | NA | 58.00% | 83.00% | NA | 55.00% | 31.00% |
| RFA | 100 | 42.00% | 67.00% | 32.00% | 8.00% | ||||
| Yang et al[16] | TACE+RFA | 24 | 29.00% | NA | NA | 68.00% | NA | NA | NA |
| RFA | 12 | 34.70% | 57.00% | ||||||
| Shibata et al[18] | TACE+RFA | 46 | 71.30% | 48.80% | NA | 100.00% | 100.00% | 84.80% | NA |
| RFA | 43 | 74.30% | 29.70% | 100.00% | 88.80% | 84.50% | |||
| Morimoto et al[20] | TACE+RFA | 19 | 67.00% | NA | 100.00% | 93.00% | 93.00% | NA | |
| RFA | 18 | 56.00% | 28.00% | 89.00% | 89.00% | 80.00% | |||
| Kang et al[22] | TACE+RFA | 19 | NA | NA | NA | 84.20% | 42.10% | 36.80% | NA |
| RFA | 18 | 66.10% | 22.20% | 16.70% | |||||
| Shen et al[23] | TACE+RFA | 18 | 63.90% | 50.00% | NA | 87.50% | NA | 73.30% | NA |
| RFA | 16 | 30.00% | 18.70% | 52.20% | 20.40% | ||||
| Zhang et al[24] | TACE+RFA | 15 | NA | NA | NA | 100.00% | NA | NA | NA |
| RFA | 15 | 80.00% | |||||||
- Citation: Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013; 19(24): 3872-3882
- URL: https://www.wjgnet.com/1007-9327/full/v19/i24/3872.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i24.3872